180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has regained Nasdaq compliance under listing rule 5250(c)(1). As previously disclosed in the current report on Form 8-K, filed by 180 Life Sciences with the Securities and Exchange Commission (“SEC”) on April 19, 2021, the Nasdaq Listing Qualifications Department notified the company that it did not comply with Nasdaq Listing Rule 5250(c)(1) because it had not yet filed with the SEC its annual report on Form 10-K for the year ended Dec. 31, 2020, or its quarterly report on Form 10-Q for the quarter ended March 31, 2021. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the SEC. Nasdaq provided the company 60 days, or until June 15, 2021, to submit a plan detailing how it intended to regain compliance with Nasdaq’s listing rules regarding timely filings. The company timely submitted such plan and, as previously reported in the current report on Form 8-K filed with the SEC on June 28, 2021, and on June 22, 2021, the company received notice from Nasdaq that it was granted an extension until July 31, 2021, to regain compliance with the listing rule. Thereafter, on July 9, 2021, the company submitted its 2020 Form 10-K with the SEC and on July 19, 2021, submitted its Q1 2021 Form 10-Q with the SEC. On July 19, 2021, Nasdaq notified 180 Life Sciences that, due to the filing of the previously untimely reports, it has determined that the company has regained compliance with Nasdaq Listing Rule 5250(c)(1) and that this matter is now closed.
To view the full press release, visit https://ibn.fm/atSev
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’ primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.